Your Messages Inbox
Your Article Summary
See Latest ArticlesTrabectedin: the evidence for its place in therapy in the treatment of soft tissue sarcoma
Core Evidence, 08/25/09
Thornton KA – Trabectedin is a potential therapeutic option for the management of softtissue sarcoma. It appears to have specific activity in a select group of histologies, most notably myxoid/round cell liposarcoma. Although it would be helpful to study the use of trabectedin in a randomized, controlled fashion, the relative rarity of soft–tissue sarcoma, and heterogeneity of the histologic subtypes, makes phase III trials a difficult prospect.
Related Articles
Coincident expression of beta-catenin and cyclin D1 in endometrial stromal tumors and related high-grade sarcomas
Modern Pathology, 11/11/09
Relevance Score: 92%
Histiocytic sarcoma with interdigitating dendritic cell differentiation: A case report with fine needle aspiration cytology and review of literature
Diagnostic Cytopathology, 10/28/09
Relevance Score: 90%
Skeletal metastasis from sarcoma: a report of three cases
European Journal of Orthopaedic Surgery & Traumatology, 10/23/09
Relevance Score: 89%
Alveolar soft-part sarcoma of the tongue in a 17-month-old
ENT Journal, 10/19/09
Relevance Score: 89%
Radiological assessment following thermoradiation therapy for primary pleural synovial sarcoma: case report
Medical Oncology, 10/19/09
Relevance Score: 89%
Today in Drug Trials...keeping you current
Receive free subspecialty "5-minute updates" via email
The Unintended Consequences of Clinical Trials Regulations
PLoS Medicine, 12/04/09
Characterization of Baseline Methicillin-Resistant Staphylococcus aureus Isolates Recovered from Phase IV Clinical Trial for Linezolid
Journal of Clinical Microbiology, 12/03/09
Bayer Starts Phase III Trial with Florbetaben
BayNews International, 12/01/09
Article Search
Sponsor